REFILE-Astellas pulls antibiotic drug candidate in Europe

(Corrects spelling of antibiotic in headline)

TOKYO Oct 24 (Reuters) - Astellas Pharma Inc (4503.T) said on Friday it has withdrawn its submission of a new antibiotic drug candidate in Europe following an unfavourable review by European regulators but hopes to refile with additional data.

The drug called Telavacin is also under review in the United States, and an advisory panel to the U.S. regulators is scheduled to hold a review of the drug on Nov. 19. (Reporting by Yumiko Nishitani)